Zobrazeno 1 - 10
of 563
pro vyhledávání: '"Peter Rossing"'
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure
Autor:
Lars Køber, David C. Wheeler, Peter Rossing, Pardeep S. Jhund, Investigators, F Martinez, Hiddo J.L. Heerspink, Dapa-Hf Trial Committees, Niels Jongs, Fan Fan Hou, Mikaela Sjöstrand, Robert D. Toto, Ricardo Correa-Rotter, Marc S. Sabatine, Dapa-Ckd, Cecilia Karlsson, Magnus Lindberg, Kieran F. Docherty, Priya Vart, John J.V. McMurray, David L. DeMets, Anna Maria Langkilde, Silvio E. Inzucchi, Glenn M. Chertow, Scott D. Solomon, Mikhail Kosiborod, Olof Bengtsson, Bergur V. Stefánsson, Piotr Ponikowski
Publikováno v:
Lancet Diabetes & Endocrinology, 24-34. ELSEVIER SCIENCE INC
STARTPAGE=24;ENDPAGE=34;ISSN=2213-8587;TITLE=Lancet Diabetes & Endocrinology
STARTPAGE=24;ENDPAGE=34;ISSN=2213-8587;TITLE=Lancet Diabetes & Endocrinology
BACKGROUND: Chronic kidney disease and heart failure are insulin resistant states associated with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type 2 diabetes in a pooled analysis of patient-level data from the D
Autor:
Daniel Wilson, Peter Rossing, Amer Joseph, Peter Kolkhof, Charlie Scott, Luis M. Ruilope, Stefan D. Anker, Bertram Pitt, Robert Lawatscheck, George L. Bakris, Rajiv Agarwal, Gerasimos Filippatos
Publikováno v:
J Am Soc Nephrol
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Background: Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type 2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia with finerenone and placebo in FIDELIO-DKD. Methods: This post hoc s
Autor:
Michał Nowicki, Bergur V. Stefánsson, C. David Sjöström, Fan Fan Hou, Dapa-Ckd Trial Committees, Niels Jongs, John J.V. McMurray, Peter Rossing, Ricardo Correa-Rotter, Glenn M. Chertow, Robert D. Toto, Investigators, David C. Wheeler, István Wittmann, Hiddo J.L. Heerspink, Anna Maria Langkilde, Tom Greene
Publikováno v:
Wheeler, D C, Jongs, N, Stefansson, B, Chertow, G M, Greene, T, Hou, F F, Langkilde, A M, McMurray, J J, Rossing, P, Nowicki, M, Wittmann, I, Correa-Rotter, R, Sjostrom, C D, Toto, R D, Heerspink, H J L & DAPA-CKD Trial Comm Investigators 2022, ' Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis : a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial ', Nephrology Dialysis Transplantation, vol. 37, no. 9, pp. 1647–1656 . https://doi.org/10.1093/ndt/gfab335
Background Despite renin–angiotensin–aldosterone system blockade and immunosuppressive treatment, focal segmental glomerulosclerosis (FSGS) often progresses to kidney failure. The objective of this prespecified analysis of the dapagliflozin and p
Autor:
Lesley A, Inker, Nwamaka D, Eneanya, Josef, Coresh, Hocine, Tighiouart, Dan, Wang, Yingying, Sang, Deidra C, Crews, Alessandro, Doria, Michelle M, Estrella, Marc, Froissart, Morgan E, Grams, Tom, Greene, Anders, Grubb, Vilmundur, Gudnason, Orlando M, Gutiérrez, Roberto, Kalil, Amy B, Karger, Michael, Mauer, Gerjan, Navis, Robert G, Nelson, Emilio D, Poggio, Roger, Rodby, Peter, Rossing, Andrew D, Rule, Elizabeth, Selvin, Jesse C, Seegmiller, Michael G, Shlipak, Vicente E, Torres, Wei, Yang, Shoshana H, Ballew, Sara J, Couture, Neil R, Powe, Andrew S, Levey
Publikováno v:
The New England journal of medicine, vol. 385, no. 19, pp. 1737-1749
Inker, L A, Eneanya, N D, Coresh, J, Tighiouart, H, Wang, D, Sang, Y, Crews, D C, Doria, A, Estrella, M M, Froissart, M, Grams, M E, Greene, T, Grubb, A, Gudnason, V, Gutierrez, O M, Kalil, R, Karger, A B, Mauer, M, Navis, G, Nelson, R G, Poggio, E D, Rodby, R, Rossing, P, Rule, A D, Selvin, E, Seegmiller, J C, Shlipak, M G, Torres, V E, Yang, W, Ballew, S H, Couture, S J, Powe, N R, Levey, A S & Chronic Kidney Dis Epidemiology Co 2021, ' New Creatinine-and Cystatin C-Based Equations to Estimate GFR without Race ', New England Journal of Medicine, vol. 385, pp. 1737-1749 . https://doi.org/10.1056/NEJMoa2102953
The New England journal of medicine, vol 385, iss 19
New England Journal of Medicine, 385(19), 1737-1749. MASSACHUSETTS MEDICAL SOC
Inker, L A, Eneanya, N D, Coresh, J, Tighiouart, H, Wang, D, Sang, Y, Crews, D C, Doria, A, Estrella, M M, Froissart, M, Grams, M E, Greene, T, Grubb, A, Gudnason, V, Gutierrez, O M, Kalil, R, Karger, A B, Mauer, M, Navis, G, Nelson, R G, Poggio, E D, Rodby, R, Rossing, P, Rule, A D, Selvin, E, Seegmiller, J C, Shlipak, M G, Torres, V E, Yang, W, Ballew, S H, Couture, S J, Powe, N R, Levey, A S & Chronic Kidney Dis Epidemiology Co 2021, ' New Creatinine-and Cystatin C-Based Equations to Estimate GFR without Race ', New England Journal of Medicine, vol. 385, pp. 1737-1749 . https://doi.org/10.1056/NEJMoa2102953
The New England journal of medicine, vol 385, iss 19
New England Journal of Medicine, 385(19), 1737-1749. MASSACHUSETTS MEDICAL SOC
New Equations for Estimating GFR without Race Equations for estimating GFR with serum creatinine overestimate measured GFR in Blacks. The authors report new equations, without race as an inflation factor, using cystatin C and creatinine that reduced
Autor:
Dapa-Ckd Trial Committees, David C. Wheeler, John J.V. McMurray, C. David Sjöström, Peter Rossing, Glenn M. Chertow, Niels Jongs, Anna Maria Langkilde, Hiddo J.L. Heerspink, Robert D. Toto, Ricardo Correa-Rotter, Investigators, Bergur V. Stefánsson, Tom Greene
Publikováno v:
Lancet Diabetes & Endocrinology, 9(11), 743-754. ELSEVIER SCIENCE INC
BACKGROUND: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change
Autor:
John J.V. McMurray, Niels Jongs, Scott D. Solomon, C. David Sjöström, Ricardo Correa-Rotter, Investigators, Douwe Postmus, Glenn M. Chertow, Peter Rossing, Robert D. Toto, Bergur V. Stefánsson, Fan Fan Hou, Dapa-Ckd Trial Committees, Hiddo J.L. Heerspink, David C. Wheeler, Anna Maria Langkilde
Publikováno v:
JACC. Heart failure, 9(11), 807-820. ELSEVIER SCI LTD
McMurray, J J V, Wheeler, D C, Stefánsson, B V, Jongs, N, Postmus, D, Correa-Rotter, R, Chertow, G M, Hou, F F, Rossing, P, Sjöström, C D, Solomon, S D, Toto, R D, Langkilde, A M, Heerspink, H J L & DAPA-CKD Trial Committees and Investigators 2021, ' Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure ', JACC: Heart Failure, vol. 9, no. 11, pp. 807-820 . https://doi.org/10.1016/j.jchf.2021.06.017
McMurray, J J V, Wheeler, D C, Stefánsson, B V, Jongs, N, Postmus, D, Correa-Rotter, R, Chertow, G M, Hou, F F, Rossing, P, Sjöström, C D, Solomon, S D, Toto, R D, Langkilde, A M, Heerspink, H J L & DAPA-CKD Trial Committees and Investigators 2021, ' Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure ', JACC: Heart Failure, vol. 9, no. 11, pp. 807-820 . https://doi.org/10.1016/j.jchf.2021.06.017
OBJECTIVES: The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF).BACKGROUND: Patients with CKD, with and without type 2 diabetes, were enrolled in the
Autor:
Peter Rossing
Publikováno v:
Nephrology Dialysis Transplantation. 38:34-40
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on Diabetes Management in Chronic Kidney Disease from 2020 comes at an opportune time when progress in diabetes technology and therapeutics offers new options to manage
Autor:
Niels Jongs, Anna Maria Langkilde, John J.V. McMurray, Robert D. Toto, Fan Fan Hou, Ricardo Correa-Rotter, Bergur V. Stefánsson, Priya Vart, Hiddo J.L. Heerspink, David Wheeler, José Luis Górriz, Glenn M. Chertow, C. David Sjöström, Peter Rossing
Publikováno v:
Journal of the American Society of Nephrology, 32(8), 2352-2361. AMER SOC NEPHROLOGY
Chertow, G M, Vart, P, Jongs, N, Toto, R D, Gorriz, J L, Hou, F F, McMurray, J J V, Correa-Rotter, R, Rossing, P, Sjöström, C D, Stefánsson, B V, Langkilde, A M, Wheeler, D C & Heerspink, H J L 2021, ' Effects of dapagliflozin in stage 4 chronic kidney disease ', Journal of the American Society of Nephrology, vol. 32, no. 9, pp. 2352-2361 . https://doi.org/10.1681/ASN.2021020167
J Am Soc Nephrol
Chertow, G M, Vart, P, Jongs, N, Toto, R D, Gorriz, J L, Hou, F F, McMurray, J J V, Correa-Rotter, R, Rossing, P, Sjöström, C D, Stefánsson, B V, Langkilde, A M, Wheeler, D C & Heerspink, H J L 2021, ' Effects of dapagliflozin in stage 4 chronic kidney disease ', Journal of the American Society of Nephrology, vol. 32, no. 9, pp. 2352-2361 . https://doi.org/10.1681/ASN.2021020167
J Am Soc Nephrol
BACKGROUND: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and
Autor:
Peter Rossing, Niina Sandholm, Nicoline Uglebjerg, Carol Forsblom, Perttu J. Lindsberg, Tarunveer S. Ahluwalia, Emma H. Dahlström, Valma Harjutsalo, Lena M. Thorn, Per-Henrik Groop, Nina Mars, Jani Saksi
Publikováno v:
Diabetes. 70:2391-2401
Fatty-acid binding protein 4 (FABP4) is implicated in the pathogenesis of cardiometabolic disorders. Pharmacological inhibition or genetic deletion of FABP4 improves cardiometabolic health and protects against atherosclerosis in preclinical models. A
Autor:
Peter Rossing
Publikováno v:
ADA Clinical Compendia. 2021:8-12
Whereas the symptoms of chronic kidney disease (CKD) in diabetes are few, there are many risk factors and biomarkers that can be used to identify individuals at high risk for development of this complication, and many of these are targets for interve